tirzepatide direct to consumer Zepbound, a popular weight loss drug, is getting a big price cut — maker Eli Lilly says it will sell one-dose vials of the drug for half the usual monthly list price., Dr. Celine Gounder breaks down Lilly launches lower-price weight-loss drug

Pending positive outcomes from ongoing and forthcoming RCTs, GLP-1 RA medications may become a pharmacotherapeutic approach for treating polysubstance use. Alcohol Addiction Among all substances, alcohol is by far the most investigated when it comes to GLP-1 RAs

For people who do lose coverage of Zepbound, drugmaker Eli Lilly has expanded access through LillyDirect, a company platform that helps coordinate telehealth services and fill prescriptions for patients who pay out-of-pocket

Learn more: See this in-depth Ozempic (semaglutide) article

Key criteria from Cigna's GLP-1 Coverage Policy: [5] BMI (body mass index) 30 (or 27 with hypertension, type 2 diabetes, sleep apnea, cardiovascular disease) 3 months documented lifestyle efforts (diet and exercise in your medical record) No concurrent GLP-1 use can't take Wegovy with Ozempic or other GLP-1 medications Renewal: Must lose 5% of starting weight to continue coverage Cigna Decision Timelines For medical services (not prescriptions), standard reviews take 5-7 business days

Consistency is key to getting the best results

Therefore, using extreme models of physiology to understand the role of these receptor signaling pathways may uncover important mediators in gut plasticity